• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GBA 杂合子不足通过改变帕金森病前驱模型中的脂质代谢加速α-突触核蛋白病理。

GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease.

机构信息

Department of Neurology Kyoto University Graduate School of Medicine, Kyoto, Japan.

Laboratory for Molecular Membrane Neuroscience, RIKEN Brain Science Institute, Saitama, Japan.

出版信息

Hum Mol Genet. 2019 Jun 1;28(11):1894-1904. doi: 10.1093/hmg/ddz030.

DOI:10.1093/hmg/ddz030
PMID:30689867
Abstract

Parkinson's disease (PD) is characterized by dopaminergic (DA) cell loss and the accumulation of pathological alpha synuclein (asyn), but its precise pathomechanism remains unclear, and no appropriate animal model has yet been established. Recent studies have shown that a heterozygous mutation of glucocerebrosidase (gba) is one of the most important genetic risk factors in PD. To create mouse model for PD, we crossed asyn Bacterial Artificial Chromosome transgenic mice with gba heterozygous knockout mice. These double-mutant (dm) mice express human asyn in a physiological manner through its native promoter and showed an increase in phosphorylated asyn in the regions vulnerable to PD, such as the olfactory bulb and dorsal motor nucleus of the vagus nerve. Only dm mice showed a significant reduction in DA cells in the substantia nigra pars compacta, suggesting these animals were suitable for a prodromal model of PD. Next, we investigated the in vivo mechanism by which GBA insufficiency accelerates PD pathology, focusing on lipid metabolism. Dm mice showed an increased level of glucosylsphingosine without any noticeable accumulation of glucosylceramide, a direct substrate of GBA. In addition, the overexpression of asyn resulted in decreased GBA activity in mice, while dm mice tended to show an even further decreased level of GBA activity. In conclusion, we created a novel prodromal mouse model to study the disease pathogenesis and develop novel therapeutics for PD and also revealed the mechanism by which heterozygous gba deficiency contributes to PD through abnormal lipid metabolism under conditions of an altered asyn expression in vivo.

摘要

帕金森病(PD)的特征是多巴胺能(DA)细胞丧失和病理性α-突触核蛋白(asyn)的积累,但确切的发病机制仍不清楚,也尚未建立合适的动物模型。最近的研究表明,葡萄糖脑苷脂酶(gba)的杂合突变是 PD 的最重要遗传风险因素之一。为了创建 PD 的小鼠模型,我们将 asyn 细菌人工染色体转基因小鼠与 gba 杂合敲除小鼠杂交。这些双突变(dm)小鼠通过其天然启动子以生理方式表达人源 asyn,并在易患 PD 的区域(如嗅球和迷走神经背核)中显示出 asyn 的磷酸化增加。只有 dm 小鼠表现出黑质致密部 DA 细胞的显著减少,表明这些动物适合作为 PD 的前驱模型。接下来,我们研究了 GBA 不足加速 PD 病理学的体内机制,重点关注脂质代谢。dm 小鼠表现出葡糖基神经酰胺苷水平升高,而没有明显的葡糖基神经酰胺积累,葡糖基神经酰胺是 GBA 的直接底物。此外,asyn 的过表达导致小鼠中 GBA 活性降低,而 dm 小鼠则倾向于表现出甚至更低的 GBA 活性。总之,我们创建了一种新型前驱小鼠模型,以研究疾病发病机制并为 PD 开发新的治疗方法,还揭示了杂合 gba 缺陷通过体内改变的 asyn 表达导致异常脂质代谢对 PD 的贡献的机制。

相似文献

1
GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease.GBA 杂合子不足通过改变帕金森病前驱模型中的脂质代谢加速α-突触核蛋白病理。
Hum Mol Genet. 2019 Jun 1;28(11):1894-1904. doi: 10.1093/hmg/ddz030.
2
Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.葡糖神经鞘氨醇在突变型GBA相关帕金森病中促进α-突触核蛋白病变。
J Neurosci. 2017 Oct 4;37(40):9617-9631. doi: 10.1523/JNEUROSCI.1525-17.2017. Epub 2017 Aug 28.
3
α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.α-突触核蛋白 BAC 转基因小鼠表现出类似 RBD 的行为和嗅觉减退:一种前驱性帕金森病模型。
Brain. 2020 Jan 1;143(1):249-265. doi: 10.1093/brain/awz380.
4
Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.β-葡萄糖脑苷脂酶的调节增加了帕金森病小鼠模型中α-突触核蛋白的分泌和外泌体释放。
Hum Mol Genet. 2018 May 15;27(10):1696-1710. doi: 10.1093/hmg/ddy075.
5
α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.α-突触核蛋白积累和 GBA 缺陷归因于 L444P GBA 突变导致 MPTP 诱导的帕金森病。
Mol Neurodegener. 2018 Jan 8;13(1):1. doi: 10.1186/s13024-017-0233-5.
6
Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.脑内给予配体-ASO 缀合物可选择性降低双突变人 A30P*A53T*α-突触核蛋白转基因小鼠单胺能神经元中 α-突触核蛋白的积累。
Int J Mol Sci. 2021 Mar 13;22(6):2939. doi: 10.3390/ijms22062939.
7
Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.神经元病 GBA1L444P 突变加速了葡萄糖脑苷脂神经酰胺水平的升高和海马α-突触核蛋白包涵体的形成。
J Neurosci. 2023 Jan 18;43(3):501-521. doi: 10.1523/JNEUROSCI.0680-22.2022. Epub 2022 Dec 7.
8
The effect of mutant GBA1 on accumulation and aggregation of α-synuclein.突变 GBA1 对α-突触核蛋白积累和聚集的影响。
Hum Mol Genet. 2019 Jun 1;28(11):1768-1781. doi: 10.1093/hmg/ddz005.
9
Lipid accumulation drives cellular senescence in dopaminergic neurons.脂滴堆积导致多巴胺能神经元衰老。
Aging (Albany NY). 2024 Jul 19;16(14):11128-11133. doi: 10.18632/aging.206030.
10
[GBA mutations and Parkinson's disease].[GBA基因突变与帕金森病]
Sheng Li Xue Bao. 2018 Jun 25;70(3):294-300.

引用本文的文献

1
Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease.健康与疾病中的脂质代谢:帕金森病的机制与治疗见解
Chin Med J (Engl). 2025 Jun 20;138(12):1411-1423. doi: 10.1097/CM9.0000000000003627. Epub 2025 May 26.
2
AAV delivery of GBA1 suppresses α-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models.通过腺相关病毒递送GBA1可抑制帕金森病模型中α-突触核蛋白的积累,并恢复戈谢病模型中的功能。
PLoS One. 2025 May 7;20(5):e0321145. doi: 10.1371/journal.pone.0321145. eCollection 2025.
3
Development of selective nanomolar cyclic peptide ligands as GBA1 enzyme stabilisers.
作为GBA1酶稳定剂的选择性纳摩尔环状肽配体的开发。
RSC Chem Biol. 2025 Jan 31;6(4):563-570. doi: 10.1039/d4cb00218k. eCollection 2025 Apr 2.
4
A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy.一种基于脂质纳米颗粒的少突胶质细胞特异性mRNA疗法。
Mol Ther Nucleic Acids. 2024 Nov 5;35(4):102380. doi: 10.1016/j.omtn.2024.102380. eCollection 2024 Dec 10.
5
A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy.一种用于研究少突胶质细胞中α-突触核蛋白聚集的新型小鼠模型:对多系统萎缩中神经胶质细胞质内含物的意义。
Mol Brain. 2024 May 24;17(1):28. doi: 10.1186/s13041-024-01104-7.
6
Experimental Animal Models of Prodromal Parkinson's Disease.前驱期帕金森病的实验动物模型。
J Parkinsons Dis. 2024;14(s2):S369-S379. doi: 10.3233/JPD-230393.
7
Axonal Transport of Lysosomes Is Unaffected in Glucocerebrosidase-Inhibited iPSC-Derived Forebrain Neurons.溶酶体的轴突运输在葡糖脑苷脂酶抑制的 iPSC 衍生的前脑神经元中不受影响。
eNeuro. 2023 Oct 10;10(10). doi: 10.1523/ENEURO.0079-23.2023. Print 2023 Oct.
8
GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.GBA1基因变异与帕金森病:为靶向治疗铺平道路。
J Mov Disord. 2023 Sep;16(3):261-278. doi: 10.14802/jmd.23023. Epub 2023 Jun 12.
9
Pathological mechanisms of neuroimmune response and multitarget disease-modifying therapies of mesenchymal stem cells in Parkinson's disease.帕金森病神经免疫反应的病理机制及间充质干细胞的多靶点疾病修饰治疗。
Stem Cell Res Ther. 2023 Apr 12;14(1):80. doi: 10.1186/s13287-023-03280-0.
10
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.葡萄糖脑苷脂(溶酶体神经酰胺)作为戈谢病的可靠生物标志物:叙述性综述。
Orphanet J Rare Dis. 2023 Feb 13;18(1):27. doi: 10.1186/s13023-023-02623-7.